Kamada, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Wasserman from Benchmark Co. maintained a Buy rating on the stock and has a $15.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Robert Wasserman has given his Buy rating due to a combination of factors that highlight Kamada’s strong financial performance and growth potential. The company reported impressive second-quarter results for 2025, with revenues surpassing expectations and earnings per share showing significant improvement compared to the previous year. This growth was driven by increased sales across various regions and products, alongside effective cost management that boosted adjusted EBITDA.
Additionally, Kamada’s ongoing R&D efforts, particularly in their Phase 3 clinical trial for inhaled Alpha-1 Antitrypsin therapy, and expansion of plasma collection capabilities, underscore its commitment to innovation and future revenue streams. The company’s financial health is further supported by a solid cash position, despite a recent special dividend distribution. Given these positive developments and the potential for substantial share price appreciation, Wasserman maintains a Buy rating with a 12-18 month price target of $15.
In another report released yesterday, TR | OpenAI – 4o also upgraded the stock to a Buy with a ILA2,821.00 price target.